Non-specific transfer factor from normal (non-cancer diseases) in the peripheral blood, tonsil, or spleen cells extracted. In theory, non-specific transfer factor, although this may be passed as anti-TB immunity, but can not provide tumor specific immunity. The wide variety of sources (such as white blood cells from healthy blood donors Administrators gain), extraction easier, so more clinical applications, many of the treated patients can feel the condition has improved to different degrees, where the objective therapeutic effect was seen only in a handful of people, and not significant and lasting effect.
Specifically sensitized lymphocytes can be used to extract specific transfer factor. Instead of sensitized lymphocytes with the transfer factor can prevent between donor and recipient histocompatibility antigens caused by differences in graft rejection and graft-versus-host reaction. Specific transfer factor can be obtained from:
The tumor specific cytotoxicity of lymphocytes in patients with osteosarcoma of relatives and close contacts, can be treated osteosarcoma.
Tumor metastasis factor infectious mononucleosis syndrome patients can be treated nasopharyngeal carcinoma. Specific transfer factor with the treatment of malignant lymphoma, non-specific effect of transfer factor seems more significant. However, as the source of difficulties, few cases of treatment, efficacy is hard to objective evaluation.
- Transfer Factor Cancer
- transfer factor and gall bladder cancer